Condition: Lung Cancer · Venous Thromboembolism · Arterial Thromboembolism · Sponsor: Beijing Chao Yang Hospital
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are: 1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors? Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.
This description comes directly from the study's public registry record.
Yuhui Zhang · 86+13520108369 · zhangyhcy@163.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
| The Fourth Hospital of Inner Mongolia Autonomous Region | Hohhot, Inner Mongolia, China | Recruiting |
| Beijing Chaoyang Hospital, Capital Medical University | Beijing, China | Recruiting |
| Beijing Luhe Hospital, Capital Medical University | Beijing, China | Recruiting |
| China-japan Friendship Hospital | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06950697